Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 198

1.

Sipuleucel-T: Prototype for development of anti-tumor vaccines.

Carballido E, Fishman M.

Curr Oncol Rep. 2011 Apr;13(2):112-9. doi: 10.1007/s11912-011-0152-5. Review.

PMID:
21243538
[PubMed - indexed for MEDLINE]
2.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
[PubMed - indexed for MEDLINE]
3.

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.

Sims RB.

Vaccine. 2012 Jun 19;30(29):4394-7. doi: 10.1016/j.vaccine.2011.11.058. Epub 2011 Nov 26. Review.

PMID:
22122856
[PubMed - indexed for MEDLINE]
Free Article
4.

Sipuleucel-T: in metastatic castration-resistant prostate cancer.

Plosker GL.

Drugs. 2011 Jan 1;71(1):101-8. doi: 10.2165/11206840-000000000-00000. Review.

PMID:
21175243
[PubMed - indexed for MEDLINE]
5.

Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.

Thara E, Dorff TB, Pinski JK, Quinn DI.

Maturitas. 2011 Aug;69(4):296-303. doi: 10.1016/j.maturitas.2011.04.012. Epub 2011 May 31. Review.

PMID:
21621934
[PubMed - indexed for MEDLINE]
6.

Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.

McKarney I.

Issues Emerg Health Technol. 2007 Sep;(101):1-4.

PMID:
17763575
[PubMed - indexed for MEDLINE]
7.

Cancer immunotherapy: sipuleucel-T and beyond.

Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P.

Pharmacotherapy. 2011 Aug;31(8):813-28. doi: 10.1592/phco.31.8.813. Review.

PMID:
21923608
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Sipuleucel-T (APC8015) for prostate cancer.

So-Rosillo R, Small EJ.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1163-7. Review.

PMID:
17020451
[PubMed - indexed for MEDLINE]
9.

Sipuleucel-T for the treatment of advanced prostate cancer.

Frohlich MW.

Semin Oncol. 2012 Jun;39(3):245-52. doi: 10.1053/j.seminoncol.2012.02.004. Review.

PMID:
22595047
[PubMed - indexed for MEDLINE]
10.

Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.

Buonerba C, Ferro M, Di Lorenzo G.

Expert Rev Anticancer Ther. 2011 Jan;11(1):25-8. doi: 10.1586/era.10.180. Review.

PMID:
21166508
[PubMed - indexed for MEDLINE]
11.

Sipuleucel-T for the treatment of prostate cancer.

Harzstark AL, Small EJ.

Drugs Today (Barc). 2008 Apr;44(4):271-8. Review.

PMID:
18536785
[PubMed - indexed for MEDLINE]
12.

Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.

Patel PH, Kockler DR.

Ann Pharmacother. 2008 Jan;42(1):91-8. Epub 2007 Dec 19. Review.

PMID:
18094343
[PubMed - indexed for MEDLINE]
13.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Di Lorenzo G, Ferro M, Buonerba C.

BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16. Review.

PMID:
22177289
[PubMed - indexed for MEDLINE]
14.

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.

Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.

Cancer Control. 2013 Jan;20(1):7-16. Review.

PMID:
23302902
[PubMed - indexed for MEDLINE]
Free Article
15.

Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).

Harzstark AL, Small EJ.

Expert Opin Biol Ther. 2007 Aug;7(8):1275-80. Review.

PMID:
17696825
[PubMed - indexed for MEDLINE]
16.

The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.

Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.

Eur Urol. 2012 Apr;61(4):639-47. doi: 10.1016/j.eururo.2011.10.027. Epub 2011 Oct 24. Review.

PMID:
22036643
[PubMed - indexed for MEDLINE]
17.

The evolving role of immunotherapy in prostate cancer.

Gerritsen WR.

Ann Oncol. 2012 Sep;23 Suppl 8:viii22-7. doi: 10.1093/annonc/mds259. Review.

PMID:
22918924
[PubMed - indexed for MEDLINE]
Free Article
18.

Prostate cancer vaccines: current status and future potential.

Doehn C, Böhmer T, Kausch I, Sommerauer M, Jocham D.

BioDrugs. 2008;22(2):71-84. Review.

PMID:
18345705
[PubMed - indexed for MEDLINE]
19.

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

Cheever MA, Higano CS.

Clin Cancer Res. 2011 Jun 1;17(11):3520-6. doi: 10.1158/1078-0432.CCR-10-3126. Epub 2011 Apr 6.

PMID:
21471425
[PubMed - indexed for MEDLINE]
Free Article
20.

Beyond sipuleucel-T: immune approaches to treating prostate cancer.

Cheng ML, Fong L.

Curr Treat Options Oncol. 2014 Mar;15(1):115-26. doi: 10.1007/s11864-013-0267-z. Review.

PMID:
24402184
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk